Does Sapropterin Affect Growth Rate?
Sapropterin (Kuvan), used to lower blood phenylalanine in phenylketonuria (PKU), shows no significant impact on linear growth rate in clinical trials. In a 6-year study of children aged 4+ starting treatment, height velocity remained within normal ranges for age and sex, matching untreated PKU historical controls.[1][2] Short-term trials (up to 10 weeks) also reported no growth disruptions.[3]
What Do Long-Term Studies Show?
A 10-year open-label extension trial tracked 87 patients (ages 0-20 at baseline). Median height z-scores stayed stable (-0.3 to -0.1), with no evidence of growth deceleration linked to sapropterin. Weight and BMI z-scores were similarly unaffected, even at doses up to 20 mg/kg/day.[1] Puberty timing aligned with norms.
How Does PKU Untreated Affect Growth?
Untreated PKU often slows growth due to high phenylalanine disrupting metabolism. Sapropterin-responsive patients achieve better Phe control than diet alone, preserving growth without adding risks. Non-responders may still need strict diet to avoid stunting.[2][4]
Any Reports of Growth Issues?
Post-marketing data and trials note rare transient side effects like headache or rash, but no causal link to impaired growth. Pediatric labels warn of monitoring growth in PKU generally, not sapropterin specifically. No black-box warnings apply.[3][5]
Factors Influencing Growth on Treatment